CYP19A1 and breast cancer: In the context of breast cancer, an estrogen-dependent cancer, where the use of aromatase inhibitors has been highly researched [47–51], deleterious effects of non-specific delivery of Letrozole includes osteoporosis leading to increased bone fractures, joint and muscle pain, menopausal symptoms, depression, cardiac problems, increased cholesterol and increased blood pressure were shown.